Cargando…

Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study

BACKGROUND: High dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied. METHODS: A new model that allowed long...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekkering, Frank C, Neumann, Avidan U, Brouwer, Johannes T, Levi-Drummer, Rachel S, Schalm, Solko W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64636/
https://www.ncbi.nlm.nih.gov/pubmed/11801193
http://dx.doi.org/10.1186/1471-230X-1-14
_version_ 1782120136558247936
author Bekkering, Frank C
Neumann, Avidan U
Brouwer, Johannes T
Levi-Drummer, Rachel S
Schalm, Solko W
author_facet Bekkering, Frank C
Neumann, Avidan U
Brouwer, Johannes T
Levi-Drummer, Rachel S
Schalm, Solko W
author_sort Bekkering, Frank C
collection PubMed
description BACKGROUND: High dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied. METHODS: A new model that allowed longitudinal changes in the parameters of viral dynamics was used in a group of genotype-1 patients (N = 15) with dose reduction from 10 to 3 million units of interferon daily in combination with ribavirin, in comparison to a control group (N = 9) with no dose reduction. RESULTS: Dose reduction gave rise to a complex viral kinetic pattern, which could be only explained by a decrease in interferon effectiveness in blocking virion production. The benefit of the rapid initial viral decline following the high induction dose is lost after dose reduction. In addition, in some patients also the second phase viral decline slope, which is highly predictive of success of treatment, was impaired by the dose reduction resulting in smaller percentage of viral clearance in the dose reduction group. CONCLUSIONS: These findings, while explaining the failure of many induction schedules, suggest that for genotype-1 patients induction therapy should be continued till HCVRNA negativity in serum in order to increase the sustained response rate for chronic hepatitis C.
format Text
id pubmed-64636
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-646362002-01-23 Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study Bekkering, Frank C Neumann, Avidan U Brouwer, Johannes T Levi-Drummer, Rachel S Schalm, Solko W BMC Gastroenterol Research Article BACKGROUND: High dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied. METHODS: A new model that allowed longitudinal changes in the parameters of viral dynamics was used in a group of genotype-1 patients (N = 15) with dose reduction from 10 to 3 million units of interferon daily in combination with ribavirin, in comparison to a control group (N = 9) with no dose reduction. RESULTS: Dose reduction gave rise to a complex viral kinetic pattern, which could be only explained by a decrease in interferon effectiveness in blocking virion production. The benefit of the rapid initial viral decline following the high induction dose is lost after dose reduction. In addition, in some patients also the second phase viral decline slope, which is highly predictive of success of treatment, was impaired by the dose reduction resulting in smaller percentage of viral clearance in the dose reduction group. CONCLUSIONS: These findings, while explaining the failure of many induction schedules, suggest that for genotype-1 patients induction therapy should be continued till HCVRNA negativity in serum in order to increase the sustained response rate for chronic hepatitis C. BioMed Central 2001-12-13 /pmc/articles/PMC64636/ /pubmed/11801193 http://dx.doi.org/10.1186/1471-230X-1-14 Text en Copyright © 2001 Bekkering et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Bekkering, Frank C
Neumann, Avidan U
Brouwer, Johannes T
Levi-Drummer, Rachel S
Schalm, Solko W
Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
title Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
title_full Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
title_fullStr Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
title_full_unstemmed Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
title_short Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
title_sort changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64636/
https://www.ncbi.nlm.nih.gov/pubmed/11801193
http://dx.doi.org/10.1186/1471-230X-1-14
work_keys_str_mv AT bekkeringfrankc changesinantiviraleffectivenessofinterferonafterdosereductioninchronichepatitiscpatientsacasecontrolstudy
AT neumannavidanu changesinantiviraleffectivenessofinterferonafterdosereductioninchronichepatitiscpatientsacasecontrolstudy
AT brouwerjohannest changesinantiviraleffectivenessofinterferonafterdosereductioninchronichepatitiscpatientsacasecontrolstudy
AT levidrummerrachels changesinantiviraleffectivenessofinterferonafterdosereductioninchronichepatitiscpatientsacasecontrolstudy
AT schalmsolkow changesinantiviraleffectivenessofinterferonafterdosereductioninchronichepatitiscpatientsacasecontrolstudy